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   ABSTRACT 
  Aim      To measure the level of agreement and application 
of 10 international recommendations for treating 
rheumatoid arthritis (RA) to a target of remission/low 
disease activity.   
  Methods      A 10-point Likert scale (1=fully disagree, 
10=fully agree) measured the level of agreement with 
each of 10 recommendations. A 4-point Likert scale 
(never, not very often, very often, always) assessed 
the degree to which each recommendation was being 
applied in current daily practice. If respondents answered 
‘never’ or ‘not very often’, they were asked whether they 
would change their practice according to the particular 
recommendation.  
  Results      A total of 1901 physicians representing 
34 countries participated. Both agreement with and 
application of recommendations was high. With regard 
to application of recommendations in daily practice, the 
majority of responses were ‘always’ and ‘very often’. 
A signiﬁ  cant percentage of participants who were 
currently not applying these recommendations in clinical 
practice were willing to change their practice according 
to the recommendations.   
  Conclusion      The results of this survey demonstrated 
great support of ‘Treating RA to Target’ recommendations 
among the international rheumatology community. 
Additional efforts may be needed to encourage 
application of the recommendations among certain 
clinicians who are resistant to changing their practice.           
  INTRODUCTION 
  Treating to therapeutic targets has become a 
standard of care for many chronic conditions.    1       –       4    
In order to set similar standards for rheumatoid 
arthritis (RA), an international task force was 
established consisting of 68 rheumatologists and 
patients with RA from 25 countries.   5    The ﬁ  rst phase 
of this Treat to Target (T2T) initiative focused on 
deﬁ  ning therapeutic targets and establishing paths 
to optimal outcomes. Based on a systematic lit-
erature review    6    and expert opinion, a consensus 
on a set of 10 recommendations was formulated 
(see appendix 1 in online supplement  ).    5    The goal 
of these 10 recommendations is to provide rheu-
matologists, patients and other stakeholders with 
clear approaches as to how to reach the set targets 
and provide patients with RA with the best qual-
ity of care available. 
  The second phase of the T2T initiative aims at 
acceptance and implementation of these recom-
mendations in daily rheumatology practice. It was 
deemed important to learn to what extent indi-
vidual components of the T2T recommendations 
are accepted (or acceptable) by rheumatologists of 
individual countries. Here we provide the results 
from an international survey of rheumatologists 
performed to this end. 
  The objectives of the survey were: (1) to evaluate 
the level of agreement with T2T recommendations 
on a global scale; (2) to determine whether and to 
what degree these recommendations were cur-
rently applied in daily practice; and (3) to assess the 
willingness of those clinicians not already applying 
these recommendations to modify their practice.   
  METHODS 
  Recruitment was determined by the steering com-
mittees of individual countries. Rheumatologists 
were contacted by email or fax and asked to anony-
mously complete a paper- or web-based question-
naire. The ﬁ  rst part of the questionnaire gathered 
demographic information. A 10-point Likert scale 
(1=fully disagree, 10=fully agree) measured the 
level of agreement with each of the 10 recommen-
dations. The degree to which each recommenda-
tion was being applied in current daily practice was 
assessed on a 4-point Likert scale (never, not very 
often, very often, always). Those who answered 
that they have ‘never’ or ‘not very often’ applied 
a speciﬁ  c recommendation in their practice were 
asked whether they would change their practice 
according to the particular recommendation. Data 
are presented using standard summary statistics 
including analysis of variance and χ  2   analysis.   
  RESULTS 
  Demographic  data 
  A total of 1901 rheumatologists participated, rep-
resenting 34 countries, nine from Western Europe 
(n=722, 38%), nine from Eastern Europe (n=403, 
21%), six from Latin America (n=436, 23%), 
Australia, Canada and New Zealand (n=107, 6%), 
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‘never’ or ‘not very often’ responses (8.1% and 7.4%, respec-
tively, p<0.0001). Similarly, for recommendation 6, χ  2   analysis 
indicated that the Canada–New Zealand–Australia group had 
more than expected ‘never’ and ‘not very often’ responses 
(32.7%, p<0.0001). For recommendation 6, participating rheu-
matologists from the Middle East also showed a relatively low 
level of application in daily practice (27.78% indicating ‘never’ 
or ‘not very often’, p<0.0001). Middle Eastern countries had 
more than expected ‘never’ or ‘not very often’ responses for rec-
ommendations 7 (18.6%, p<0.0001) and 9 (13.9%, p=0.0012). 
  Subgroup analysis revealed no statistically signiﬁ  cant differ-
ences in acceptance or application of T2T recommendations 
between rheumatologists in academic institutions and those 
in community clinics (data not shown). For both academic and 
community practice-based participants, the level of agreement 
was highest for recommendation 10 (9.2) and lowest for rec-
ommendation 5 (8.4 for academic and 8.5 for community-based 
participants). In addition, the results did not change signiﬁ  cantly 
when clinicians who see <30 patients/month (n=522) were 
excluded from the analysis. The agreement with recommenda-
tions 10 and 5 were 9.3 and 8.5, respectively.   
    Willingness to change practice according to the 
recommendations 
  A signiﬁ  cant proportion of responders who were currently not 
applying T2T recommendations were willing to change their 
practice according to the recommendations (  ﬁ  gure 3  ). However, 
43.1% and 32.8% of participants who were currently not apply-
ing recommendations 5 and 6, respectively, indicated that they 
would not change their practice according to these recommenda-
tions. Furthermore, although only 6.7% and 6.5% of participants 
indicated that they were not applying T2T recommendations 3 
and 4, respectively, a high percentage of these (30.5% for recom-
mendation 3 and 45.4% for recommendation 4) indicated that 
they were unwilling to change their practice to accommodate 
these recommendations.   
  Although there were no clear regional differences in terms 
of willingness to change practice for recommendations 3, 5, 8, 
9 and 10, the Canada–New Zealand–Australia group showed 
greater than expected ‘not willing to change practice’ responses 
for recommendations 1 (p<0.05), 2 (p<0.05), 4 (p<0.0001), 6 
(p<0.0001) and 7 (p=0.0017).     
Japan and Korea (n=156, 8%) and ﬁ  ve from the Middle East 
(n=75, 4%). The response rates were highly variable between 
the countries and dependent on the means of survey distribu-
tion. For example, in Japan where 131 university-based rheu-
matologists were contacted, the response rate was 100%. In 
contrast, in countries such as Italy where potential participants 
were selected and contacted using national directories, the 
response rates were signiﬁ  cantly lower at approximately 3%. 
  Practices in university hospitals, general hospitals and private 
clinics were represented with 41%, 33% and 18% of respon-
dents, respectively. The mean number of participants’ years in 
practice was 17.4 (range 3 months to 52 years). The average 
number of patients with RA seen per month was 81 (range 1 
to 600).   
    Agreement with the recommendations 
  Agreement with T2T recommendations    5    was very high, with 
each of the 10 recommendations receiving a score of >8.0 (  ﬁ  g-
ure 1  ). Recommendations 1 and 10 received the highest agree-
ment scores (9.2 and 9.3, respectively). The level of agreement 
with these two recommendations was relatively high (>8) across 
all countries and regions. Recommendations 5 and 3 received 
the lowest overall agreement scores (8.5 and 8.6, respectively).   
  The largest variations in agreement scores between countries 
were noted for recommendations 5 and 6, with scores ranging 
from 9.6 to 6.9 for both. The agreement with recommendations 
5 (7.1), 6 (7.4) and 8 (7.6) was signiﬁ  cantly lower for the Canada–
New Zealand–Australia group than for any other region.   
    Application of T2T recommendations to daily practice 
  The majority of responses were ‘always’ and ‘very often’, rang-
ing from 97.7% for recommendation 2 to 87.3% for recommen-
dation 5 (  ﬁ  gure 2  ). Recommendations 5 (regular documentation 
of disease activity) and 6 (use of composite activity measures 
that include joint counts) received the highest number of ‘never’ 
or ‘not very often’ responses (12.7% and 10.0% for recommen-
dations 5 and 6, respectively).   
  For recommendation 5, χ  2   analysis indicated that, based on 
the null hypothesis (ie, no difference between groups), the 
Canada–New Zealand–Australia group had more than expected 
‘never’ and ‘not very often’ responses (29.9%, p<0.0001) whereas 
Eastern Europe and Latin America had fewer than expected 
 Figure  1        Average disagree/agree scores for the 10 individual recommendations. The response rate was >99%.       
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  Two elements of the T2T recommendations received the most 
objections: recommended frequency of monitoring and the use 
of validated composite measures of disease activity in routine 
clinical practice to guide treatment decisions. While certain logis-
tical aspects of clinical practice (ie, high patient volume, lack of 
support, etc) may inﬂ  uence clinicians’ attitudes towards these 
two aspects of the T2T recommendations, some participants 
also commented that a tight monitoring schedule is not neces-
sary as long as the patient is showing improvement (data not 
shown). These attitudes may inadvertently undermine the quest 
for remission as a treatment goal, since remission is deﬁ  ned using 
various individual measures or indices.    7    Thus, efforts should 
be deployed to help clinicians integrate these validated tools 
into their routine clinical practice, especially since simple tools 
like the Simpliﬁ  ed Disease Activity Index and Clinical Disease 
Activity Index are available, which can also be used to deﬁ  ne 
remission according to the American College of Rheumatology 
(ACR) and European League against Rheumatism (EULAR).    7    
  In this regard, it is interesting to note that recommendation 3 
received one of the lowest mean scores, which is somewhat at 
odds with most strategic trials which aimed for low disease activ-
ity.    6        8        9    One possible explanation is that clinicians strive towards 
remission, and low disease activity is a second-best outcome. 
  The data collected from this questionnaire should be inter-
preted in the context of the survey sample and data collection 
methodology. One limitation was that the method of survey 
dissemination was determined by the steering committees of 
individual countries and was not standardised. It is therefore dif-
ﬁ  cult to ascertain the precise number of rheumatologists from 
each country who received the survey and consequently the 
response rates. It is also important to recognise that a selection 
bias towards rheumatologists more positive towards the T2T 
recommendations is possible, and responses might not be repre-
sentative of the global rheumatology community. Finally, deter-
mination whether and to what extent these recommendations 
are currently applied in daily practice might not be accurately 
assessed with the chosen methodology; practice audits such as 
  DISCUSSION 
  The results of this multinational recommendations assessment 
questionnaire indicated that the majority of responders were 
current with the latest developments in the management of RA 
and were presumably treating their patients accordingly. They 
also revealed a high level of support and interest in the T2T ini-
tiative and, where this was not the case, a willingness to change 
practice to meet these recommendations. Furthermore, attitudes 
toward individual recommendations pointed to the areas where 
additional effort may be needed in order to provide optimal care 
to all patients with RA. 
 Figure  2        Application of each of the 10 recommendations in daily practice.       
 Figure  3        Willingness to change practice. NoA, no answer.          
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the Assessment in Rheumatology (AIR)   project are better suited 
to answer the question.    10    The survey nonetheless identiﬁ  ed 
resistance towards certain aspects of the recommendations and 
the results can serve as a preliminary guide for future global, 
national and regional programmes. 
  These survey results may contribute to: (1) increasing aware-
ness of the T2T concept which is being recommended and 
advocated by the main organisations EULAR, ACR and several 
national societies; (2) identifying speciﬁ  c local issues that need to 
be addressed in order to advance patient care; (3) demonstrating 
to non-responders to the survey, regardless of the reason for lack 
of participation, where they stand in comparison to their peers; 
and (4) focusing on the identiﬁ  cation of the speciﬁ  c national basis 
for the disagreement with certain aspects of the T2T recommen-
dations by steering committees from individual countries and 
the development of programmes that could address them in a 
manner that best ﬁ  ts local practices.     
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